



Abbott India Limited
Godrej BKC, Plot C-68, "G"Block,
15-16th Floor, Bandra-Kurla Complex,
Near MCA Club, Bandra (E),
Mumbai - 400 051. India

Registered Office:
3, Corporate Park,
Sion Trombay Road,
Mumbai - 400 071.India

Tel: (91-22) 5046 1000/2000
Fax : (91-22) 5016 9400
E-mail : webmasterindia@abbott.com
Website : www.abbott.co.in
CIN: L24239MH1944PLC007330

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

August 7, 2020

Scrip Code: 500488

Dear Sir/Madam,

Sub: Intimation under Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose a text of Unaudited Financial Results of the Company for the first quarter ended on June 30, 2020, approved by the Board of Directors at its Meeting held on Friday, August 7, 2020 along with the Limited Review Report issued by S R B C & CO. LLP, Statutory Auditors of the Company.

The Meeting of the Board of Directors of the Company commenced at 7.45 pm and concluded at 10.25 pm.

Kindly acknowledge the receipt of the same.

Thank you.

Yours faithfully,

Abbott India Limited

KRUPA

KETAN

ANANDPAR

A

Digitally signed by KRUPA KETAN ANANDPARA
DN: c=IN, o=Personal,
postalCode=400067, st=Maharashtra,
2.5.4.0=0ba2c4b7ce570e0b53e3d85907
7995ca02373468056b444ec4f9a345f23
5d,
serialNumber=403741809046b20a1dcff7
39fec336d107711a1104b6ca03e6fee9511
706a74, cn=KRUPA KETAN ANANDPARA
Date: 2020.08.07 22:31:53 +05'30'

Krupa Anandpara

Company Secretary

Membership No.: ACS 16536



Abbott India Limited
Godrej BKC, Plot C-68, "G"Block,
15-16th Floor, Bandra-Kurla Complex,
Near MCA Club, Bandra (E),
Mumbai - 400 051, India

Registered Office:
3, Corporate Park,
Sion Trombay Road,
Mumbai - 400 071, India

Tel: (91-22) 5046 1000/2000
Fax : (91-22) 5016 9400
E-mail : webmasterindia@abbott.com
Website : www.abbott.co.in
CIN: L24239MH1944PLC007330

Statement of unaudited results for the quarter ended June 30, 2020

(Rs. in Lakhs except earnings per share)

Particulars	Quarter ended			Year ended
	June 30, 2020	March 31, 2020	June 30, 2019	March 31, 2020
	Unaudited	Audited	Unaudited	Audited
		Refer Note 4		
1 Income				
(a) Revenue from operations	1064,27	961,20	998,89	4093,14
(b) Other income	27,63	28,13	29,60	114,39
Total Income	1091,90	989,33	1028,49	4207,53
2 Expenses				
(a) Cost of materials consumed	125,73	139,27	99,14	451,76
(b) Purchases of stock-in-trade	541,50	486,25	446,84	1802,64
(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(57,19)	(69,92)	14,01	61,25
(d) Employee benefits expense	128,48	116,31	120,18	476,11
(e) Finance costs	4,45	2,82	2,03	8,53
(f) Depreciation and amortisation expense	14,10	14,81	14,80	59,61
(g) Other expenses	92,33	150,86	144,54	544,94
Total Expenses	849,40	840,40	841,54	3404,84
3 Profit before tax (1-2)	242,50	148,93	186,95	802,69
4 Tax expenses				
(a) Current tax expense	63,60	36,76	70,80	208,04
(b) Tax adjustment for earlier years	-	-	-	25
(c) Deferred tax expense/(credit)	(1,45)	1,20	(79)	1,47
Total Tax Expenses	62,15	37,96	70,01	209,76
5 Profit for the period (3-4)	180,35	110,97	116,94	592,93
6 Other Comprehensive Income				
Items that will not be reclassified subsequently to Profit or Loss	(1,35)	(2,98)	(80)	(5,40)
Income tax on above	34	75	28	45
Total Other Comprehensive Income, net of tax	(1,01)	(2,23)	(52)	(4,95)
7 Total Comprehensive Income for the period, net of tax (5+6)	179,34	108,74	116,42	587,98
8 Paid-up Equity Share Capital (Face Value of Rs.10 per Equity Share)	21,25	21,25	21,25	21,25
9 Earnings per equity share - Basic/Diluted (of Rs.10/- each) (not annualised)	84.87	52.22	55.03	279.04

NOTES :

- 1 The above financial results have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meetings held on August 7, 2020.
- 2 The financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular dated July 5, 2016.
- 3 The financial results for quarter ended June 30, 2020 have been subjected to limited review by the statutory auditors of the Company. The Limited Review Report does not contain any qualifications.
- 4 The figures for the quarter ended March 31, 2020 as reported in these financial results are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the relevant financial year which were only reviewed and not subjected to audit.
- 5 The extended lockdown on account of COVID-19 pandemic has led to a slowdown of demand in some therapeutic areas and resulted in lower sales. The Company continues to ensure uninterrupted supply of products to meet the needs of our customers. The Company's manufacturing operations at Goa are operating at sufficient capacity with adequate measures of social distancing and safety to help ensure a healthy workplace for the employees on-site. Office-based work continues to be conducted remotely. While the national lockdown has been eased in some states, field employees are returning to the field as per the specified government regulations.
The Management has exercised due care, made reasonable judgements and estimates, inter alia, in determining carrying amounts of trade receivables, property, plant & equipment, inventories and other financial assets based on the information available to date, while preparing the financial results as of and for the quarter ended June 30, 2020. The Company continues to closely monitor the situation and will take appropriate measures in an attempt to mitigate any adverse impact.
- 6 The Company has only one segment which is 'Pharmaceuticals'. Therefore, disclosure relating to segments is not applicable and accordingly not made.
- 7 Figures for the previous periods have been regrouped/reclassified wherever considered necessary.

For and on behalf of the Board of Directors of
Abbott India Limited

**RAJIV
BALKRISHNA
SONALKER**

Digitally signed by RAJIV BALKRISHNA
SONALKER
DN: c=IN, o=Personal,
2.5.4.20=338c357c4d66d754dc5353fa5c4aa
d42263a1bc7ccc316c4574b219cc81a406,
postalCode=400076, st=MAHARASHTRA,
serialNumber=e08dc922fe696031cd8985
2f73214b16a7308f199f15c8410c5dce91f
c, cn=RAJIV BALKRISHNA SONALKER
Date: 2020.08.07 22:28:36 +05'30'

Place : Mumbai
Date : August 7, 2020

Rajiv Sonalker
Whole-time Director and CFO
DIN : 07900178

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

**Review Report to
The Board of Directors
Abbott India Limited**

1. We have reviewed the accompanying statement of unaudited financial results of Abbott India Limited (the "Company") for the quarter ended June 30, 2020 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For SRBC & CO LLP
Chartered Accountants
ICAI Firm registration number: 324982E/E300003

Digitally signed by RAVI KAILASH
BANSAL
DN: cn=RAVI KAILASH BANSAL,
c=IN, o=Personal,
email=ravi.bansal@srb.in
Date: 2020.08.07 20:22:50 +05'30'

per Ravi Bansal
Partner
Membership No.: 49365
UDIN: 20049365AAAACF3869
Place: Mumbai
Date: August 07, 2020